Healthcare Equipment and Supplies
Company Overview of SynCardia Systems, Inc.
SynCardia Systems, Inc., a medical technology company, focuses on developing, manufacturing, and commercializing the SynCardia temporary Total Artificial Heart (TAH-t) in the United States, European Union, and Canada. Its SynCardia TAH-t is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The company was founded in 2001 and is headquartered in Tucson, Arizona.
1992 East Silverlake Road
Tucson, AZ 85713
Founded in 2001
Key Executives for SynCardia Systems, Inc.
Chief Executive Officer, President and Director
Co-Founder, Chief Scientific & Medical Officer and Chairman of Science Advisory Board
Senior Vice President of Regulatory Affairs and Quality
Vice President of Communications
Compensation as of Fiscal Year 2015.
SynCardia Systems, Inc. Key Developments
SynCardia Systems Seeks Acquisitions
Aug 17 15
SynCardia Systems, Inc. is seeking acquisitions. SynCardia Systems, Inc. has filed an IPO in the amount of $40.00 million, the net proceeds of which will be used to in-license, acquire, or invest in complementary businesses, technologies, products or assets.
SynCardia Systems, Inc. Receives FDA Approval to Conduct an Investigational Device Exemption Clinical Study on the Effective Use of 50cc SynCardia Temporary Total Artificial Heart
Mar 31 15
SynCardia Systems, Inc. has received FDA approval to conduct an Investigational Device Exemption (IDE) clinical study on the effective use of its 50cc SynCardia temporary Total Artificial Heart. The FDA approval will allow SynCardia to launch the study with as many as 30 heart failure patients. Patients enrolled in this study will receive the 50cc SynCardia Total Artificial Heart as a bridge to a donor heart transplant. Under the study, the 50cc SynCardia Total Artificial Heart initially will be available for implantation in - 10 pediatric patients 10-18 years old - 10 adult patients 19-75 years old - 10 patients who would not otherwise qualify under the study criteria. This secondary arm is expected to further characterize the use of the 50cc SynCardia Heart. All patients in the study must be eligible for donor heart transplant. As part of the study and to better understand the patient populations that can benefit from the 50cc SynCardia Heart, images of the patients' chest cavities will undergo 3D modeling. Study data through the first six months of patient use will be provided to the FDA as part of its review and approval process. Patients will be followed for up to two years to report on their experiences.
Dan Hudspeth Joins SynCardia Systems, Inc. as Chief Financial Officer
Feb 24 15
Dan Hudspeth has been named Chief Financial Officer of SynCardia Systems, Inc. Hudspeth has an extensive background in financing, accounting, manufacturing and distribution within high-growth private equity-based and public companies. A certified public accountant inactive, Hudspeth most recently provided interim executive and board advisory services to venture capital and private equity-backed companies though his company, Cohesive Strategy LLC.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 15, 2014